Welsch Lukas, May Andrea, Blasberg Tobias, Wetzka Jens, Müller Elisa, Heilani Myriam, Friedrich-Rust Mireen, Knabe Mate
Department of Gastroenterology and Hepatology, Hospital of the Johann Wolfgang Goethe University Frankfurt, Frankfurt, Germany.
Department of Gastroenterology, Oncology and Pneumology, Asklepios Paulinen Klinik, Wiesbaden, Germany.
Clin Endosc. 2023 Mar;56(2):194-202. doi: 10.5946/ce.2022.121. Epub 2023 Mar 9.
BACKGROUND/AIMS: Endoscopic therapy for neoplastic Barrett's esophagus (BE) has become the standard of care over the past two decades. In clinical practice, we regularly encounter patients who fail to achieve complete squamous epithelialization of the esophagus. Although the therapeutic strategies in the individual stages of BE, dysplasia, and esophageal adenocarcinoma are well studied and largely standardized, the problem of inadequate healing after endoscopic therapy is only marginally considered. This study aimed to shed light on the variables influencing inadequate wound healing after endoscopic therapy and the effect of bile acid sequestrants (BAS) on healing.
Retrospective analysis of endoscopically treated neoplastic BE in a single referral center.
In 12.1% out of 627 patients, insufficient healing was present 8 to 12 weeks after previous endoscopic therapy. The average follow-up duration was 38.8±18.4 months. Complete healing was achieved in 13 patients already after intensifying proton pump inhibitor therapy. Out of 48 patients under BAS, 29 patients (60.4%) showed complete healing. An additional eight patients (16.7%) improved, but only partial healing was achieved. Eleven (22.9%) patients showed no response to BAS augmented therapy.
In cases of insufficient healing even under exhaustion of proton pump inhibitors, treatment with BAS can be an option as an ultimate healing attempt.
背景/目的:在过去二十年中,内镜治疗肿瘤性巴雷特食管(BE)已成为标准治疗方法。在临床实践中,我们经常遇到食管未能实现完全鳞状上皮化生的患者。尽管BE、发育异常和食管腺癌各个阶段的治疗策略已得到充分研究且基本标准化,但内镜治疗后愈合不足的问题仅得到了极少的关注。本研究旨在阐明影响内镜治疗后伤口愈合不足的变量以及胆汁酸螯合剂(BAS)对愈合的影响。
对单个转诊中心接受内镜治疗的肿瘤性BE进行回顾性分析。
在627例患者中,12.1%的患者在先前内镜治疗后8至12周存在愈合不足。平均随访时间为38.8±18.4个月。在强化质子泵抑制剂治疗后,13例患者实现了完全愈合。在48例接受BAS治疗的患者中,29例(60.4%)实现了完全愈合。另外8例患者(16.7%)有所改善,但仅实现了部分愈合。11例(22.9%)患者对BAS强化治疗无反应。
即使在质子泵抑制剂治疗无效的愈合不足病例中,使用BAS治疗作为最终的愈合尝试可能是一种选择。